PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition

Oncogene

Volumn 35, Issue 18, 2016, Pages 2333-2344

  Meng, Z ^a   Jia, L F ^a   Gan, Y H ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; LYSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRICHOSTATIN A; TUBACIN; VORINOSTAT; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID; PTEN PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLUORESCENCE MICROSCOPY; GLIOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE; ACETYLATION; ANIMAL; CELL MEMBRANE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; PROTEIN TRANSPORT; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYSINE; MICE; NEOPLASM INVASIVENESS; PROTEIN TRANSPORT; PTEN PHOSPHOHYDROLASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939435005     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.293     Document Type: Article

References (48)

1. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362
2. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947
3. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124-2129
4. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935-3940
5. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998; 16: 3397-3402
6. Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW, Gutkind JS. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia 2013; 15: 461-471
7. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378
8. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998; 95: 15406-15411
9. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J., et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5, -trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999; 96: 6199-6204
10. Leslie NR, Yang X, Downes CP, Weijer CJ. The regulation of cell migration by PTEN. Biochem Soc Trans 2005; 33: 1507-1508
11. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK., et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001; 98: 4622-4627
12. Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci USA 2006; 103: 3633-3638
13. Iijima M, Huang YE, Luo HR, Vazquez F, Devreotes PN. Novel mechanism of PTEN regulation by its phosphatidylinositol 4,5-bisphosphate binding motif is critical for chemotaxis. J Biol Chem 2004; 279: 16606-16613
14. Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene 2007; 26: 3930-3940
15. Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J 2004; 379: 301-307
16. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y., et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99: 323-334
17. Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA 2003; 100: 7491-7496
18. Lumb CN, Sansom MS. Defining the membrane-Associated state of the PTEN tumor suppressor protein. Biophys J 2013; 104: 613-621
19. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 2004; 429: 123-133
20. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T., et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun 2012; 3: 911
21. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci USA 2009; 106: 480-485
22. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784
23. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. J Biol Chem 2006; 281: 26562-26568
24. Dekker FJ. Histone acetyl transferases as emerging drug targets. Drug Discovery Today 2009; 14: 942-948
25. Witt O, Deubzer HE, Milde T, Oehme I HDAC family: What are the cancer relevant targets?. Cancer Lett 2009; 277: 8-21
26. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008; 28: 1688-1701
27. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T., et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 2008; 68: 7561-7569
28. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389-4394
29. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D., et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002; 21: 6820-6831
30. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV., et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-607
31. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S., et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005; 24: 4531-4539
32. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A., et al. HDAC6 is a microtubule-Associated deacetylase. Nature 2002; 417: 455-458
33. Altonsy MO, Habib TN, Andrews SC. Diallyl disulfide-induced apoptosis in a breast-cancer cell line (MCF-7) may be caused by inhibition of histone deacetylation. Nutr Cancer 2012; 64: 1251-1260
34. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-5170
35. Kim HR, Kim EJ, Yang SH, Jeong ET, Park C, Lee JH., et al. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptormediated and mitochondrial pathway?. Exp Mol Med 2006; 38: 616-624
36. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG., et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36: 233-240
37. Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C., et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003; 38: 59-69
38. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005; 25: 1608-1619
39. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16: 1111-1120
40. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int J Oncol 2004; 25: 1509-1519
41. Gan YH, Zhang S. PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol 2009; 45: e150-e154
42. Kou XX, Hao T, Meng Z, Zhou YH, Gan YH. Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion. Carcinogenesis 2013; 34: 58-67
43. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 2000; 60: 7033-7038
44. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612-626
45. Dallavalle S, Pisano C, Zunino F. Development and therapeutic impact of HDAC6- selective inhibitors. Biochem Pharmacol 2012; 84: 756-765
46. Chen CS, Weng SC, Tseng PH, Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005; 280: 38879-38887
47. Fischle W, Emiliani S, Hendzel MJ, Nagase T, Nomura N, Voelter W., et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem 1999; 274: 11713-11720
48. Oehme I, Linke JP, Bock BC, Milde T, Lodrini M, Hartenstein B., et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci USA 2013; 110: E2592-E2601